Table 1. Characteristics of Global Lipids Genetics Consortium and UK Biobank datasets.
| Exposure/outcome | Datasets | No. SNPs | Sample size (No. of cases) | Population |
|---|---|---|---|---|
| LDL-cholesterol | GLGC | 41 | 83,198 | 90% European |
| HDL-cholesterol | GLGC | 59 | 92,860 | 90% European |
| Triglycerides | GLGC | 35 | 91,598 | 90% European |
| Hepatic steatosis | GOLD | 2 | 7,176 | 100% European |
| Histological NAFLD | AGES | 2 | 2,868 | 100% European |
| LDL-cholesterol | UK Biobank | 41 | 343,621 | 100% European |
| HDL-cholesterol | UK Biobank | 59 | 315,133 | 100% European |
| Triglycerides | UK Biobank | 35 | 343,992 | 100% European |
| Main outcome | ||||
| Gallstone disease | UK Biobank | 371,714 (10,520) | 100% European |
LDL, low-density lipoprotein; HDL, high-density lipoprotein; NAFLD, non-alcoholic fatty liver disease; GLGC, Global Lipids Genetics Consortium; GOLD, Genetics of Obesity-related Liver Disease; AGES, Age, Gene/Environment Susceptibility-Reykjavik Study; SNPs, single-nucleotide polymorphisms.